Physician profile
Kari E Reeves
NPI 1598893646
$2,769.06
in general payments reported to CMS, 2019-2025
20 companies · $1,089 in 2025
The $1,089 reported for 2025 was more than what 82% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $98.13 · 2022: $256 · 2023: $669 · 2024: $657 · 2025: $1,089.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,415.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,414.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $608.02 | 2022-2025 | |
| Alkermes, INC. | $416.26 | 2021-2025 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $302.22 | 2021-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $249.66 | 2022-2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $221.41 | 2023-2025 | Austedo Xr, Uzedy, Austedo |
| E.R. Squibb & Sons, L.L.C. | $149.33 | 2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $118.47 | 2023-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Tris Pharma INC | $113.97 | 2024-2025 | Dyanavel Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $89.56 | 2023-2024 | Caplyta |
| Indivior INC. | $87.21 | 2023-2024 | Perseris |
| Axsome Therapeutics, INC. | $76.06 | 2023-2025 | Auvelity |
| Corium, LLC | $69.14 | 2025 | Azstarys |
| Lundbeck LLC | $59.18 | 2023-2024 | Rexulti |
| Masimo Corporation | $44.10 | 2022 | |
| Boston Scientific Corporation | $44.01 | 2025 | Watchman Flx |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $31.60 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $27.82 | 2022 | |
| Avion Pharmaceuticals | $23.33 | 2024 | Methylphenidate Hydrochloride |
| Collegium Pharmaceutical, INC. | $21.80 | 2025 | Belbuca |
| Supernus Pharmaceuticals, INC. | $15.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kari Reeves listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.